Foundation of Company
Company was founded in July 2013.
Obtained a WDL
The company was issued a wholesale dealers license by competent Authority - Ministry of Health. Guidelines for good practice in the distribution of human medicines have been adopted pursuant to Article 84 and Article 85 (b) (3) of Directive 2001/83 / EC and brought by Serbian MoH and published in “R Serbia Official Gazette” in 2016 but the Ministry is not issuing separate GDP certificate, by issuing WDL it is understood that wholesaler operates in accordance with GDP guidelines.
Establishment of strong portfolio
Through depth market analysis the company identified niche pharma products for placement on the market, with the focus on oncology and orphan drugs. Company completed registation in the register of bidders within the Serbian Bussines Registers Agency.
First supply and implementation of QMS
The company signed agreements with the most eminent health care centres in Belgrade and throughout Serbia. Started distribution to end users and also obtained and implemented ISO:9001 2008 QMS standard.
Porfolio and therapeutic area expansion
The company expanded therapeutic areas in which it is present to: haematology, cardiology, neurology, infectious diseases, anaesthesia, gastroenterology and psychiatry.
Extended reach in medicines supply
The company realised it’s first supplies to the neighbouring markets. Completed implementation of ISO:9001 2015 QMS standard.
Introduction of new generic medicines
Company successfully introduced new generic brand of medicine
that treats brain tumours and cancers that have spread elsewhere in the body (metastatic brain tumours), types of cancer that originate from white blood cells (Hodgkin’s lymphoma and non-Hodgkin’s lymphomas) and is also used as a “conditioning” treatment before transplantation of the patients own haematopoietic progenitor cells. Another new generic brand medication that is used to treat rheumatoid arthritis was also placed on the market.
Distribution of an orphan drug
The company began with distribution of targeted cancer immunotherapy, innovative and original medicine used for the treatment of high risk neuroblastoma, a rare form of cancer arising from neural crest cells, the most frequently-occurring solid tumour in infants under the age of one. This innovative medicine that is becoming standard care in the treatment of high risk neuroblastoma is now also available in Serbia, it is a vital step forward in the treatment of young children with this aggressive type of cancer. The company became member of Group of pharmaceutical wholesalers within Serbian Chamber of Commerce, which has the status of full member of GIRP- the European Healthcare Distribution Association.